Patents by Inventor Sen-itiroh Hakomori

Sen-itiroh Hakomori has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Disialofucoganglioside immunogen and fucoganglioside monosialosyl Le.sup.a II
    Patent number: 5011920
    Abstract: Disialosyl Le.sup.a (IV.sup.3 NeuAcIII.sup.6 NeuAcIII.sup.4 FucLc.sub.4), a novel human cancer-associated fucoganglioside that is highly immunogenic. Also, a hybridoma cell line (ATCC No. HB 8861) secreting a monoclonal IgG3 antibody (FH7) directed to disialosyl Le.sup.a. The disialosyl Le.sup.a antigen was detected in various cancer tissues and their cell lines but was absent in various normal tissues and blood cells. Sera of patients with various cancers, particularly early cases of colonic and gastric cancers, showed an elevated disialosyl Le.sup.a antigen level, which subsequently decreased after surgical tumor removal.
    Type: Grant
    Filed: May 5, 1989
    Date of Patent: April 30, 1991
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Sen-itiroh Hakomori, Yasuo Fukushi, Edward D. Nudelman, Steven B. Levery
  • Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
    Patent number: 4904596
    Abstract: A hybridoma cell line (ATCC No. HB 8873) secreting a monoclonal IgM antibody (FH6) directed to a fucoganglioside, 6B, which accumulates in human colonic adenocarcinoma but is absent in normal colonic mucosa. The structure of the 6B ganglioside to which the antibody FH6 is directed is as follows: ##STR1## The hybridoma secreting the antibody FH6 was selected by reactivity of the FH6 antibody with the 6B ganglioside (VI.sup.3 NeuAcV.sup.3 III.sup.3 Fuc.sub.2 nLc.sub.6) and lack of reactivity with other glycolipids, including glycolipids having closely related structures, such as sialosyllactoneotetraosylceramide (IV.sup.3 NeuAcnLc.sub.4), sialosyllactofucopentaosy(III)ceramide (IV.sup.3 NeuAcIII.sup.3 FucnLc.sub.4), sialosyllactofucopentaosy(II)ceramide (sialosyl-Le.sup.a glycolipid; IV.sup.3 NeuAcIII.sup.4 FucLc.sub.4), and 6C fucoganglioside (sialosyl 2.fwdarw.6 fucoganglioside; VI.sup.6 NeuAcIII.sup.3 FucnLc.sub.6).
    Type: Grant
    Filed: August 7, 1985
    Date of Patent: February 27, 1990
    Assignee: Fred Hutchinson Cancer Research Center
    Inventor: Sen-itiroh Hakomori
  • Monoclonal antibody defining oncofetal structure of fibronectin
    Patent number: 4894326
    Abstract: Antibody defining structure present in fibronectins from tumors and fetal tissues but absent in fibronectins from normal adult tissues and plasma; useful for diagnosing and treating human cancers.
    Type: Grant
    Filed: April 9, 1986
    Date of Patent: January 16, 1990
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Hidemitsu Matsuura, Sen-itiroh Hakomori
  • Monoclonal antibody that specifically binds to disialosyl Le.sup.a
    Patent number: 4851511
    Abstract: Disialosyl Le.sup.a (IV.sup.3 NeuAcIII.sup.6 NeuAcIII.sup.4 FucLc.sub.4), a novel human cancer-associated fucoganglioside that is highly immunogenic. Also, a hybridoma cell line (ATCC No. HB 8861)secreting a monoclonal IgG3 antibody (FH7) directed to disialosyl Le.sup.a. The disialosyl Le.sup.a antigen was detected in various cancer tissues and their cell lines but was absent in various normal tissues and blood cells. Sera of patients with various cancers, particularly early cases of colonic and gastric cancers, showed an elevated disialosyl Le.sup.a antigen level, which subsequently decreased after surgical tumor removal.
    Type: Grant
    Filed: January 30, 1986
    Date of Patent: July 25, 1989
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Sen-itiroh Hakomori, Yasuo Fukushi, Edward D. Nudelman, Steven B. Levery